Press Releases Stay on top of the latest news from Poseida Therapeutics. Learn about our leading-edge cell and gene therapy programs, from new discoveries to clinical trials, and get the most recent investor news. IR Sub Menu Investors & Media Corporate Profile Press Releases Events & Presentations Publications Year None20222021202020192018201720162015 Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022 08/11/2022 Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 08/08/2022 Poseida Therapeutics Announces Pricing of Public Offering of Common Stock 08/04/2022 Poseida Therapeutics Announces Proposed Public Offering of Common Stock 08/03/2022 Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies 08/03/2022 Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory Board 07/26/2022 Poseida Therapeutics Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T Products 06/29/2022 Poseida Therapeutics Announces Virtual 2022 Annual Meeting of Stockholders 06/02/2022 Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors 05/18/2022 Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting 05/17/2022 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 103
Year None20222021202020192018201720162015 Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022 08/11/2022 Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 08/08/2022 Poseida Therapeutics Announces Pricing of Public Offering of Common Stock 08/04/2022 Poseida Therapeutics Announces Proposed Public Offering of Common Stock 08/03/2022 Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies 08/03/2022 Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory Board 07/26/2022 Poseida Therapeutics Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T Products 06/29/2022 Poseida Therapeutics Announces Virtual 2022 Annual Meeting of Stockholders 06/02/2022 Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors 05/18/2022 Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting 05/17/2022 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 103
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022 08/11/2022
Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 08/08/2022
Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies 08/03/2022
Poseida Therapeutics Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T Products 06/29/2022
Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting 05/17/2022